1-{[4-(4-bromo-benzensulphonyloxy-2-(hex-5-enyl-methyl-carbamoyl)-cyclopentanecarbonyl)]-amino}2-vinyl-cyclopropanecarboxylic acid ethyl ester | 862175-03-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-{[4-(4-bromo-benzensulphonyloxy-2-(hex-5-enyl-methyl-carbamoyl)-cyclopentanecarbonyl)]-amino}2-vinyl-cyclopropanecarboxylic acid ethyl ester
• 英文别名: ethyl (1R,2S)-1-[[(1R,2R,4S)-4-(4-bromophenyl)sulfonyloxy-2-[hex-5-enyl(methyl)carbamoyl]cyclopentanecarbonyl]amino]-2-ethenylcyclopropane-1-carboxylate
• CAS: 862175-03-9
• 化学式: C₂₈H₃₇BrN₂O₇S
• 分子量: 625.581
• InChiKey: OOLQTVVUXIPBST-PPEVLTQXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  39
• 可旋转键数：
  15
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  128
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  1-{[4-(4-bromo-benzensulphonyloxy-2-(hex-5-enyl-methyl-carbamoyl)-cyclopentanecarbonyl)]-amino}2-vinyl-cyclopropanecarboxylic acid ethyl ester 在 二氯(邻异丙氧基苯基亚甲基)(三环己基膦)钌 作用下， 以 二氯甲烷 为溶剂， 反应 2.5h， 以60%的产率得到17-7-(4-bromo-benzensulphonyloxy)-13-methyl-2,1 4-dioxo-3,13-diaza-tricyclo[13.3.0.0*4,6*]octadec-7-ene-4-carboxylic acid ethyl ester
  参考文献：
  名称：

  [EN] HCV NS-3 SERINE PROTEASE INHIBITORS
  [FR] INHIBITEURS DE LA NS-3 SERINE PROTEASE DU VHC

  摘要：

  公开号：

  WO2005073195A3
• 作为产物：
  描述：

  1-((2-(hex-5-enyl(methyl)carbamoyl)-4-hydroxycyclopentanecarbonyl)amino)-2-vinylcyclopropanecarboxylic acid ethyl ester 、 苯磺酰氯 在 三乙烯二胺 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 以80%的产率得到1-{[4-(4-bromo-benzensulphonyloxy-2-(hex-5-enyl-methyl-carbamoyl)-cyclopentanecarbonyl)]-amino}2-vinyl-cyclopropanecarboxylic acid ethyl ester
  参考文献：
  名称：

  [EN] HCV NS-3 SERINE PROTEASE INHIBITORS
  [FR] INHIBITEURS DE LA NS-3 SERINE PROTEASE DU VHC

  摘要：

  公开号：

  WO2005073195A3

文献信息

• Hcv Ns-3 Serine Protease Inhibitors
  申请人：Rosenquist Asa

  公开号：US20070203072A1

  公开（公告）日：2007-08-30

  Peptidomimetic compounds are described which inhibit the NS3 protease of the hepatitis C virus (HCV). The compounds have the formula where the variable definitions are as provided in the specification. The compounds comprise a carbocyclic P2 unit in conjunction with a novel linkage to those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site.

  本文描述了一种抑制丙型肝炎病毒（HCV）的NS3蛋白酶的肽类类似物化合物。该化合物的化学式中，变量定义如规范中所提供。该化合物包括一个碳环P2单元，与抑制剂更远离天然底物的名义剪切位点的那些部分的新型连接结合，该连接将远侧的肽键方向相对于靠近剪切位点的肽键反转。
• HCV NS-3 SERINE PROTEASE INHIBITORS
  申请人：Rosenquist Asa

  公开号：US20100166706A1

  公开（公告）日：2010-07-01

  Methods drawn to peptidomimetic compounds which inhibit the NS3 protease of the hepatitis C virus (HCV), are described. The compounds have the formula (VI) where the variable definitions are as provided in the specification. The compounds comprise a carbocyclic P2 unit in conjunction with a novel linkage to those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site.

  本文描述了用于抑制丙型肝炎病毒（HCV）NS3蛋白酶的肽类类似物化合物的方法。这些化合物的公式为（VI），其中变量定义如规范所述。这些化合物包括一个碳环P2单元，与抑制剂更远离原生底物的部分具有新颖的连接，该连接将远离切割位点的肽键的方向与靠近切割位点的肽键的方向相反。
• HCV NS-3 serine protease inhibitors
  申请人：Medivir AB

  公开号：US10172846B2

  公开（公告）日：2019-01-08

  Methods drawn to peptidomimetic compounds which inhibit the NS3 protease of the hepatitis C virus (HCV), are described. The compounds have the formula (VI) where the variable definitions are as provided in the specification. The compounds comprise a carbocyclic P2 unit in conjunction with a novel linkage to those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site.

  本文介绍了抑制丙型肝炎病毒（HCV）NS3蛋白酶的拟肽化合物的制备方法。这些化合物具有式 (VI)，其中变量定义如说明书所提供。这些化合物包括一个碳环 P2 单元，该单元与抑制剂中离原生底物名义裂解位点较远的部分有一种新的连接，这种连接使远端肽键的方向与裂解位点近端的肽键方向相反。
• US7671032B2
  申请人：——

  公开号：US7671032B2

  公开（公告）日：2010-03-02
• Structure–activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350
  作者：Pierre Raboisson、Herman de Kock、Åsa Rosenquist、Magnus Nilsson、Lourdes Salvador-Oden、Tse-I Lin、Natalie Roue、Vladimir Ivanov、Horst Wähling、Kristina Wickström、Elizabeth Hamelink、Michael Edlund、Lotta Vrang、Sandrine Vendeville、Wim Van de Vreken、David McGowan、Abdellah Tahri、Lili Hu、Carlo Boutton、Oliver Lenz、Frederic Delouvroy、Geert Pille、Dominique Surleraux、Piet Wigerinck、Bertil Samuelsson、Kenneth Simmen

  DOI：10.1016/j.bmcl.2008.07.088

  日期：2008.9

  SAR analysis performed with a limited set of cyclopentane-containing macrocycles led to the identification of N-[17-[2-(4-isopropylthiazole-2-yl)-7-methoxy-8-methylquinolin-4-yloxy]-13-methyl-2,14-dioxo-3,13-diazatricyclo [13.3.0.0(4,6)]octadec-7-ene-4-carbonyl](cyclopropyl) sulfonamide (TMC435350, 32c) as a potent inhibitor of HCV NS3/4A protease (K-i = 0.36 nM) and viral replication (replicon EC50 = 7.8 nM). TMC435350 also displayed low in vitro clearance and high permeability, which were confirmed by in vivo pharmacokinetic studies. TMC435350 is currently being evaluated in the clinics. (C) 2008 Elsevier Ltd. All rights reserved.